3-(Chloromethyl)-5-methyl-1,2,4-oxadiazole

Catalog No. :
ACGMVB387
CAS No. :
1192-80-9
Molecular Formula :
C4H5ClN2O
Molecular Weight :
132.55

IUPAC Name:3-(chloromethyl)-5-methyl-1,2,4-oxadiazole

3-(Chloromethyl)-5-methyl-1,2,4-oxadiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g98%$96.00Login to see priceIn stockInquiry
10g98%$181.00Login to see priceIn stockInquiry
25g98%$438.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(Chloromethyl)-5-methyl-1,2,4-oxadiazole
IUPAC Name3-(chloromethyl)-5-methyl-1,2,4-oxadiazole
MDL No.MFCD01809083
Molecular FormulaC4H5ClN2O
Molecular Weight132.55
SMILESCC1=NC(CCl)=NO1
InChI KeyZFYVXZGJPJTIPQ-UHFFFAOYSA-N
Synonym3-(chloromethyl)-5-methyl-1,2,4-oxadiazole | 1192-80-9 | 3-Chloromethyl-5-methyl-[1,2,4]oxadiazole | 1,2,4-OXADIAZOLE, 3-(CHLOROMETHYL)-5-METHYL- | MFCD01809083 | 3-chloromethyl-5-methyl-1,2,4-oxadiazole | NSC184824 | SCHEMBL1170174 | DTXSID10306989 | ZFYVXZGJPJTIPQ-UHFFFA
CAS No.1192-80-9
PubChem CID302157

Safety Data

Pictogram
CorrosiveHarmful or irritant
Signal Word
Danger
Hazard Statement(s)
H302-H314
Precautionary Statement(s)
P260-P264-P270-P280-P301+P330+P331-P303+P361+P353-P304+P340-P305+P351+P338-P310-P363-P405-P501

Synthetic Route by SureRoute

1. ACGMVB387 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGHIZ628 route compound structure diagram
    ACGHIZ62825977-23-5 In Stock
  2. Then
  3. ACGMVB387 route product structure diagram
    ACGMVB3871192-80-9 In Stock
Inquiry

2. ACGMVB387 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEPDO413 route compound structure diagram
    ACEPDO4133272-96-6 In Stock
  4. Then
  5. ACGMVB387 route product structure diagram
    ACGMVB3871192-80-9 In Stock
Inquiry

Comments (0)